
Sign up to save your podcasts
Or
At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.
3.7
33 ratings
At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.
7,809 Listeners
1,760 Listeners
316 Listeners
1,299 Listeners
480 Listeners
39 Listeners
2,412 Listeners
133 Listeners
57 Listeners
2 Listeners
0 Listeners
49 Listeners
0 Listeners
3,364 Listeners
0 Listeners